dual muscarinic antagonist/beta 2 adrenoceptor agonists (AstraZeneca/Pulmagen)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual muscarinic antagonist/beta 2 adrenoceptor agonists (AstraZeneca/Pulmagen)
Drug Alias Namedual muscarinic antagonist/beta 2 adrenoceptor agonists (Argenta/AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-2 adrenergic receptor agonistsMuscarinic acetylcholine receptor antagonists
TargetsBeta-2 adrenergic receptorMuscarinic acetylcholine receptor
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArgenta Discovery
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPulmagen TherapeuticsArgenta DiscoveryAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A
Related LinksN/A